‘Guinea piggers’ at large in the pharmaceutical industry
In an exclusive interview with Outsourcing-Pharma, Weingard said her research shows as many as 12 per cent of trial subjects – or 'guinea piggers' – are dual enrolling in trials and 20 per cent of those are signing up to more than 3 trials every year.
This practice skews trial data and puts both the patient and the prosperity of the innovative pharmaceutical industry at risk, believes Weingard.
To combat clinical trial fraud, she suggests everyone in research must play a part in implementing a verification process to help bust the ‘guinea piggers’ and secure the future validity of data.
